Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Cystic Fibrosis
100%
CFTR Modulator Therapy
100%
Therapy Management
100%
Medication Management
28%
Elexacaftor-tezacaftor-ivacaftor
28%
Lumacaftor/ivacaftor
28%
Israel
14%
Clinical Outcomes
14%
Forced Expiratory Volume in 1 Second (FEV1)
14%
Significant Benefit
14%
Medication Adherence
14%
Body Mass Index
14%
First Year
14%
Treatment Regimen
14%
Clinical Trials
14%
Adverse Events
14%
Economic Burden
14%
Treatment Protocol
14%
Clinical Benefit
14%
Cost Reduction
14%
Health Condition
14%
High Cost
14%
Open Study
14%
Management System
14%
Daily Treatment
14%
Treatment Burden
14%
Multisystem Disease
14%
Cystic Fibrosis Foundation
14%
Handheld Devices
14%
Clinic Visits
14%
Index Function
14%
Pulmonary Function Test
14%
Oral Medication
14%
Body Mass Index Percentile
14%
Healthcare Providers
14%
Prospective multicenter
14%
Treatment Management
14%
Patient Engagement Platforms
14%
User Experience Questionnaire
14%
Multi-cloud Management
14%
Nursing and Health Professions
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Adherence
57%
Tezacaftor
57%
Ivacaftor
57%
Body Mass
28%
Medication Therapy Management
28%
Adverse Event
14%
Health Care Personnel
14%
Clinical Outcome
14%
Systemic Disease
14%
Forced Expiratory Volume
14%
Patient Compliance
14%
Physical Examination
14%
Lung Function Test
14%
Consent
14%
Efficacy
14%
Accident Prevention
14%
Clinical Trial
14%
Health Condition
14%
Mouth
14%
Medicine and Dentistry
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Cystic Fibrosis
100%
Ivacaftor
57%
Tezacaftor
57%
Body Mass Index
28%
Health Care Cost
28%
Clinical Trial
14%
Systemic Disease
14%
Mouth
14%
Physical Examination
14%
Patient Compliance
14%
Forced Expiratory Volume
14%
Lung Function Test
14%
Oral
14%
Health Care Personnel
14%
Management of Cystic Fibrosis
14%
Adverse Event
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Tezacaftor
57%
Ivacaftor
57%
Adverse Event
14%
Clinical Trial
14%
Systemic Disease
14%